Thus, the classification scheme showed prognostic value independent of tumor grade, IDH1/2 status, patient age and therapies (not independent of IDH1 status, age, MGMT promoter methylation and therapies in TCGA GBM samples). This evidence concerns the gene IDH1 and neoplasm.